top of page


Aro Biotherapeutics Appoints Anthony Tolcher, MD, to Scientific Advisory Board

Philadelphia, PA, May 1, 2019 --- Aro Biotherapeutics announced the appointment of Anthony Tolcher, MD, to its Scientific Advisory Board (SAB). Dr. Tolcher will provide strategic counsel on the development of novel Centyrin therapeutic candidates for oncology indications.


“We are excited and pleased to have Dr. Tolcher, a well-known leader in translational oncology clinical research join Aro’s SAB,” said Sue Dillon, PhD, Co-founder and Chief Executive Officer of Aro. “As we progress our Centyrin pipeline toward initial clinical studies in patients with cancer, Dr. Tolcher’s insights and experience will be invaluable to us.”


Dr. Tolcher is the founder and CEO of NEXT-Oncology, a clinical research organization dedicated to advancing highly innovative cancer therapeutics to Phase I clinical trials. Before founding NEXT-Oncology, Dr. Tolcher was co-founder and a leading member of START (South Texas Accelerated Research Therapeutics), managing a network of clinical trial centers across the U.S., Europe and Asia. He is a graduate of the University of British Columbia in Vancouver, Canada. He performed his residency in internal medicine at the University of Toronto, a fellowship in oncology at the University of British Columbia and a fellowship in research at the National Cancer Institute, Bethesda, Maryland. Dr. Tolcher is a board certified medical oncologist.  


Dr. Tolcher commented, “I am excited to work with Aro and its innovative platform and help guide groundbreaking new therapeutics to the clinic. The Centyrin technology has evolved with high quality science to provide the potential for significantly differentiated drug candidates.”

Building a Pipeline of Life Changing Therapies

Centyrins are small, structurally simple, ultra-stable, highly soluble proteins. These characteristics enable the discovery of medicines with new mechanisms of action for cancer and other devastating diseases. Aro’s lead program, which is a bi-specific Centyrin, is in late-stage lead optimization for advanced non-small cell lung cancer. Aro’s second therapeutic program is focused on creating a Centyrin-siRNA conjugate for other forms of cancer. This first-of-its-kind combination is designed to address unmet medical needs by targeting drug payloads in high concentration to the site of disease, while lowering the toxicity to non-target organs. The company holds an exclusive worldwide license for research, development, manufacturing and commercialization of Centyrin protein therapeutics.

About Aro Biotherapeutics

Aro is a biotechnology company focused on the research and development of a new generation of protein biologics called Centyrins. The company is developing a wholly-owned pipeline of Centyrins for oncology and immunology, and is working with leaders in the industry on leveraging Centyrins for delivery of a variety of drug payloads, including nucleic acid drugs for a diverse set of diseases. For more information, visit

Media Contact

Mike Beyer

Sam Brown Inc.


bottom of page